https://www.selleckchem.com/pr....oducts/anlotinib-al3
Diabetic nephropathy (DN) is the main cause of chronic kidney disease and end-stage renal disease worldwide. Although available clinical trials have shown that endothelin receptor (ER) antagonists may be a novel and beneficial drug for DN, no consistent conclusions regarding their sufficient effectiveness and safety for patients with DN have been presented. To assess the effectiveness and safety of ER antagonists among patients with DN. The EMBASE, PubMed, MEDLINE, Cochrane, and ClinicalTrials.gov databases were searched withou
Curtir
Comentario
Compartilhar
